Read more about the article AXSM +865%: base breakout on a clinical-stage biotech, March 2019
AXSM on the 2019-03-07 breakout entry, from my chart archive

AXSM +865%: base breakout on a clinical-stage biotech, March 2019

AXSM is back on traders' screens this week, after the FDA accepted Axsome Therapeutics' filing for a new narcolepsy drug in mid-July 2026. The chart that's worth studying, though, is…

Comments Off on AXSM +865%: base breakout on a clinical-stage biotech, March 2019